UNASSIGNED: Extracellular @entity6883 ( @entity855 ) is a signaling molecule that induces a plethora of effects ranging from the regulation of cell proliferation to modulation of cancerous cell behavior. In @entity14 , @entity855 was reported to stimulate epithelial cell proliferation and possibly promote resistance to anti- @entity5 treatments. However, the exact role of this danger-signaling molecule on cancerous intestinal epithelial cells (IECs) in response to chemotherapeutic agents remains unknown. To address how @entity855 may influence the response of cancerous IECs to chemotherapeutic agents, we used Caco-2 cells, which display enterocyte-like features, to determine the effect of @entity855 on the expression of @entity7737 ( @entity7737 ). Gene and protein expression were determined by quantitative real-time PCR (qRT-PCR) and Western blotting. Resistance to @entity2879 , @entity900 and @entity632 was determined by @entity98 assays in response to @entity855 stimulation of Caco-2 cells and in cells for which @entity7737 expression was down-regulated by shRNA. @entity855 increased the expression of @entity7737 at both the mRNA and protein levels. @entity7737 expression involved an @entity855 -dependent stimulation of the @entity8047 /ERK signaling pathway that was associated with an increase in relative resistance of Caco-2 cells to @entity2879 . Abolition of @entity7737 expression using shRNA significantly reduced the protective effect of @entity7737 toward @entity2879 as well as to @entity900 and @entity632 . This study describes the mechanism by which @entity855 may contribute to the chemoresistance of cancerous IECs in @entity14 . Given the heterogeneity of @entity14 responses to anti- @entity5 drugs, these findings call for further study to understand the role of P2 receptors in @entity5 drug therapy and to develop novel therapies aimed at regulating P2 receptor activity.

@entity7737 Expression Is Upregulated by XXXX in @entity14 Cells and Enhances Their Survival to Chemotherapeutic Drugs.

@entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity8047 :: ('5609', 'Gene') :: ['MEK'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity6883 :: ('CHEBI:15422', 'Chemical') :: ["adenosine 5'-triphosphate"] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity98 :: ('CHEBI:53233', 'Chemical') :: ['MTT'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal adenocarcinoma', 'colorectal cancer'] @entity7737 :: ('1244', 'Gene') :: ['MRP2', 'multidrug resistance-associated protein 2'] @entity855 :: ('MESH:D000255', 'Chemical') :: ['ATP']
@entity6883 :: (CHEBI:15422,Chemical) :: ['Adenosine 5'-Triphosphate']
